

Targeted Medical Nutrition in Pre-Cachectic Patients with Non-Small-Cell Lung Cancer

Citation for published version (APA):

Laviano, A., Calder, P. C., Schols, A., Lonnqvist, F., Bech, M., Dorkhan, M., & Muscaritoli, M. (2021). Targeted Medical Nutrition in Pre-Cachectic Patients with Non-Small-Cell Lung Cancer: A Subgroup Analysis. Nutrition and Cancer-An International Journal, 73(5), 899-900. https://doi.org/10.1080/01635581.2020.1773873

Document status and date:

Published: 10/03/2021

DOI:

10.1080/01635581.2020.1773873

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these

- · Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 06 Oct. 2022



LETTER TO THE EDITOR



Targeted Medical Nutrition in Pre-Cachectic Patients with Non-Small-Cell Lung Cancer: A Subgroup Analysis

Alessandro Laviano^a, Philip C. Calder^{b,c}, Annemie Schols^d, Fredrik Lonnqvist^e, Maria Bech^f, Mozhgan Dorkhan^f, and Maurizio Muscaritoli^a

^aDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy; ^bHuman Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK; ^cNIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK; ^dDepartment of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands; ^eDepartment of Molecular Medicine and Surgery and the Centre for Molecular Medicine, Karolinska Institute, Stockholm, Sweden; ^fSmartfish AS, Oslo, Norway

Nutritional support is recommended for malnourished patients receiving anticancer treatment. In a recently executed pilot, double-blind, comparator-controlled trial evaluating the safety, and tolerability of an oral targeted medical nutrition (TMN) supplement -containing n-3 polyunsaturated fatty acids (PUFAs), vitamin D3, and whey protein – in patients with nonsmall-cell lung cancer (NSCLC), a post-hoc analysis showed that patients with pre-cachexia, i.e., subjects having early signs of cachexia, had less side effects and an improved survival vs. the comparator group that did not receive TMN (1).

Based on this potentially important observation we have looked in more detail at the subgroup of precachectic individuals that had received oral TMN. No significant differences were observed between precachectic on control (n=14) and pre-cachectic on TMN (n=14) in adverse event profile, body composition and metabolic parameters. However, the precachectic subjects on TMN were functionally improved vs. the control group in terms of grip strength (dominant arm, p=0.0415, non-dominant arm, p=0.0146) (Figure 1). This functional effect of TMN may strengthen the clinical relevance of the survival benefit previously reported (1), since grip strength has been shown to predict survival of lung cancer patients with good performance status (2).

Also, post-walk fatigue was significantly improved after 6 weeks in the TMN group (p = 0.044) but the difference between groups did not reach significance after 12 weeks.

In summary, early TMN with a specific oral nutritional supplement in pre-cachectic patients may have a positive effect on both functional parameters, i.e., grip strength, and disease survival. These data should be strengthened by adequately powered trials, yet they strongly suggest the use of nutritional support for malnourished pre-cachectic patients receiving anticancer treatment.

Authors' Contribution

All authors contributed to study design, interpretation of data and drafting of the manuscript. F. Lonnqvist and D. Mozhgan contributed to data acquisition and analysis. All authors approved the final version of the article for publication.

Disclosure Statement

A. Laviano, P.C. Calder, A. Schols, M. Muscaritoli are consultants for Smartfish AS.

Funding

This work was funded by Smartfish AB, Stockholm, Sweden.

References

 Laviano A, Calder PC, Schols A, Lonnqvist F, Bech M, Muscaritoli M. Safety and tolerability of targeted medical nutrition for cachexia in non-small-cell lung cancer: a randomized, double-blind, controlled pilot




Figure 1. Change from baseline to week 12 in grip strength in the pre-cachectic population.

trial. Nutr Cancer. 2020;72(3):439–50. doi:10.1080/01635581.2019.1634746

- 2. Burtin C, Bezuidenhout J, Sanders KJC, Dingemans AMC, Schols A, Peeters STH, Spruit MA, De Ruysscher
- D. Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy. J Cachexia Sarcopenia Muscle. 2020;11:424–431. doi:10.1002/jcsm.12526